Metraipolis › archive › dc_2d7cc8fe5435

Assessing Real World Efficacy, Safety, and 18-Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies — Europe PMC PMID:40968578

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40968578
DOI
10.1111/ene.70304
License (as archived)
solo-consultazione
Archived
2026-11-10T05:23:11.278Z
SHA-256 of the archived text
633fdd51f232b8408f8e117e150b11cdd0a1ff4d5eb134efe20f21f7a0ff13ba
Stable URL of this page
https://metraipolis.com/documento/dc_2d7cc8fe5435

How to cite

Assessing Real World Efficacy, Safety, and 18-Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies — Europe PMC PMID:40968578 — Europe PMC (en), https://europepmc.org/article/MED/40968578 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2d7cc8fe5435 (Metraipolis archive dc_2d7cc8fe5435, sha256 633fdd51f232b8408f8e117e150b11cdd0a1ff4d5eb134efe20f21f7a0ff13ba)
BibTeX
@misc{dc2d7cc8fe5435,
  title = {Assessing Real World Efficacy, Safety, and 18-Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies — Europe PMC PMID:40968578},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40968578},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2d7cc8fe5435; sha256 633fdd51f232b8408f8e117e150b11cdd0a1ff4d5eb134efe20f21f7a0ff13ba},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40968578. Agents can read the archived copy with the MCP tool read_document.